D 
Dr Soliman Abdel Kader Fakeeh Hospital Company SCJSC 4017.SR · SAR
Health Care · Tadawul · 🇸🇦 Saudi Arabia
29.94
-1.12%
Close of 9 Nov 2026, in SAR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in SAR, from our data supplier.
Revenue
SAR 3.09bn
FY2020FY2025
Net income
SAR 290.2m
FY2020FY2025
Free cash flow
−SAR 48.5m
FY2020FY2025
Shareholders' equity
SAR 3.17bn
FY2020FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Revenue | SAR 3.09bn | SAR 2.79bn | SAR 2.33bn | SAR 2.01bn | SAR 1.96bn | SAR 1.72bn |
| Gross profit | SAR 703.8m | SAR 699.0m | SAR 616.7m | SAR 600.4m | SAR 637.8m | SAR 516.5m |
| Operating income | SAR 293.1m | SAR 359.1m | SAR 334.0m | SAR 407.1m | SAR 376.4m | SAR 280.1m |
| Net income | SAR 290.2m | SAR 287.6m | SAR 279.6m | SAR 326.3m | SAR 334.3m | SAR 203.2m |
| Diluted earnings per share | 1.25 | 1.34 | 1.22 | 1.63 | 3.34 | 2.03 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Total assets | SAR 5.83bn | SAR 5.32bn | SAR 4.23bn | SAR 5.07bn | SAR 3.46bn | SAR 3.19bn |
| Cash and short-term investments | SAR 439.2m | SAR 533.8m | SAR 214.3m | SAR 316.8m | SAR 191.7m | SAR 187.2m |
| Total liabilities | SAR 2.25bn | SAR 2.00bn | SAR 2.98bn | SAR 2.91bn | SAR 1.74bn | SAR 1.79bn |
| Debt | SAR 695.2m | SAR 1.08bn | SAR 2.26bn | SAR 2.25bn | SAR 1.19bn | SAR 219.5m |
| Shareholders' equity | SAR 3.17bn | SAR 2.95bn | SAR 1.02bn | SAR 1.90bn | SAR 1.61bn | SAR 1.31bn |
| Shares outstanding | 232m | 215m | 230m | 200m | 100m | 100m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Cash from operations | SAR 471.8m | SAR 436.1m | SAR 228.6m | −SAR 14.6m | SAR 254.7m | SAR 3.6m |
| Capital spending | −SAR 520.3m | −SAR 524.8m | −SAR 376.5m | −SAR 123.6m | −SAR 80.1m | −SAR 63.7m |
| Free cash flow | −SAR 48.5m | −SAR 88.7m | −SAR 147.9m | −SAR 138.2m | SAR 174.6m | −SAR 60.1m |
| Dividends paid | −SAR 69.0m | — | −SAR 1.15bn | −SAR 35.0m | −SAR 22.6m | −SAR 22.3m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | SAR 798.9m | SAR 724.1m | SAR 799.1m | SAR 778.3m | SAR 811.8m | SAR 701.0m | SAR 742.7m | SAR 713.8m |
| Gross profit | SAR 226.8m | SAR 190.7m | SAR 169.8m | SAR 177.2m | SAR 180.6m | SAR 176.1m | SAR 164.8m | SAR 183.8m |
| Operating income | SAR 69.7m | SAR 44.6m | SAR 77.3m | SAR 70.3m | SAR 81.6m | SAR 77.0m | SAR 72.2m | SAR 104.5m |
| Net income | SAR 57.9m | SAR 38.4m | SAR 64.2m | SAR 71.6m | SAR 82.1m | SAR 72.2m | SAR 73.8m | SAR 93.6m |
| Diluted earnings per share | 0.25 | 0.17 | 0.28 | 0.31 | 0.35 | 0.31 | 0.34 | 0.44 |
| Cash from operations | −SAR 1.0m | SAR 3.0m | SAR 167.0m | SAR 325.0m | −SAR 118.0m | SAR 85.0m | SAR 188.0m | SAR 246.0m |
| Capital spending | −SAR 71.0m | −SAR 47.0m | −SAR 97.0m | −SAR 142.0m | −SAR 90.0m | −SAR 191.0m | −SAR 273.0m | −SAR 141.0m |
| Free cash flow | −SAR 72.0m | −SAR 44.0m | SAR 70.0m | SAR 183.0m | −SAR 208.0m | −SAR 106.0m | −SAR 85.0m | SAR 105.0m |
| Total assets | SAR 6.08bn | SAR 5.94bn | SAR 5.83bn | SAR 5.65bn | SAR 5.60bn | SAR 5.36bn | SAR 5.32bn | SAR 5.18bn |
| Cash and short-term investments | — | — | SAR 439.2m | SAR 391.9m | SAR 277.3m | SAR 400.4m | SAR 533.8m | SAR 755.1m |
| Debt | SAR 331.0m | SAR 334.0m | SAR 695.2m | SAR 607.5m | SAR 634.5m | SAR 561.3m | SAR 596.7m | SAR 568.3m |
| Shareholders' equity | SAR 3.19bn | SAR 3.21bn | SAR 3.17bn | SAR 3.11bn | SAR 3.03bn | SAR 3.02bn | SAR 2.95bn | SAR 2.89bn |
Financial ratios
Data as of 10 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 22.8% | 25.0% | 26.5% | 29.8% | 32.5% | 30.1% |
| Operating margin | 10.7% | 13.7% | 16.2% | 19.0% | 19.2% | 16.3% |
| Net margin | 9.4% | 10.3% | 12.0% | 16.2% | 17.0% | 11.8% |
| Return on equity | 9.1% | 9.8% | 27.4% | 17.2% | 20.7% | 15.5% |
| Return on assets | 5.0% | 5.4% | 6.6% | 6.4% | 9.6% | 6.4% |
| Free cash flow yield | 12.5% | 13.0% | 7.7% | — | — | — |
| Revenue growth | 10.7% | 20.0% | 15.6% | 2.4% | 14.5% | — |
| Earnings growth | 0.9% | 2.8% | -14.3% | -2.4% | 64.5% | — |
| Current ratio | 1.63x | 1.97x | 1.30x | 1.19x | 2.25x | 1.84x |
| Debt to equity | 0.22x | 0.20x | 1.73x | 0.37x | 0.05x | 0.17x |
| Equity ratio | 54.4% | 55.3% | 24.1% | 37.4% | 46.6% | 41.0% |
| Interest coverage | 6.75x | 4.00x | 3.09x | 12.30x | 13.15x | 7.43x |
| Buybacks as a share of market value | -7.9% | 6.5% | — | — | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 15.4% | 12.5% | — |
| Operating income | -10.4% | 0.9% | — |
| Net income | -3.8% | 7.4% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 23.9% | 25.6% | 27.2% | — |
| Operating margin | 11.1% | 13.6% | 14.7% | — |
| Net margin | 9.8% | 11.6% | 12.4% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | |
|---|---|---|
| Price to earnings | 27.3 | 50.1 |
| Price to sales | 2.6 | 5.2 |
Dividends and splits
Per share, in the currency the company pays
Paid for 1 years. Last went ex-dividend on 26 Jun 2025.
| FY2025 | |
|---|---|
| Paid in the year | 0.30 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.